CJC-1295
CJC-1295 is a synthetic GHRH analog available in two distinct forms: the DAC (Drug Affinity Complex) version, which carries a maleimidopropionic acid group that binds to albumin in plasma to extend half-life to approximately one week, and the non-DAC form ('Mod GRF 1-29'), which has a shorter half-life suited to pulsatile dosing around exercise or sleep. The DAC form produces sustained IGF-1 and GH elevation rather than mimicking the physiological pulsatile secretion pattern, which may have different metabolic consequences than pulsatile approaches. Human pharmacokinetic studies confirm dose-dependent IGF-1 elevation; combining CJC-1295 with ipamorelin significantly amplifies GH secretion via GHRH + GHRP synergy. Neither form has regulatory approval; evidence for clinically meaningful outcomes in healthy adults is limited to small studies, and long-term safety data are not established.
Evidence last reviewed: 19 Apr 2026
Not a routine supplement — not recommended for self-directed use.
Information here is educational only, not a recommendation to use. See our Safety page.
Verify this peptide on CertiPep
certipep.ch — anonymous purity & characterization service
Evidence is from research or clinical settings — does not imply safety outside supervised contexts.
CJC-1295 has shown moderate evidence for sustained GH and IGF-1 elevation in healthy adults, primarily through small randomized controlled trials. However, the lack of regulatory approval and limited long-term safety data highlight significant gaps in the evidence base.
Sustained GH and IGF-1 elevationHealthy adults · RCTModerate
CJC-1295 DAC significantly prolonged GH and IGF-1 secretion compared to baseline.